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ABSTRACT  
The potential of high resolution mass spectrometry (HRMS) for the investigation of human in vivo 
metabolism of 3,4-methylenedioxypyrovalerone (MDPV) using urine collected from a consumer (this is, 
in non-controlled experiments) has been investigated. As a control sample was not available, the common 
approach based on the comparison of a control/blank sample and samples collected after drug intake 
could not be used. Alternatively, an investigation based on common fragmentation pathways was applied, 
assuming that most metabolites share some fragments with the parent drug. An extension of this approach 
was also applied based on the fragmentation pathway of those metabolites identified in urine samples in 
the first step. The use of MSE experiments (sequential acquisition of mass spectra at low and high 
collision energy) has been crucial to this aim as it allowed promoting fragmentation in the collision cell 
without any previous precursor ion selection. MDPV belongs to the group of new psychoactive 
substances (NPS), being known as the “cannibal drug”. This substance is being more and more abused 
and associated with dangerous side effects. The human metabolites (both phase I and phase II) were 
detected and tentatively identified by accurate-mass full-spectrum measurements using ultra-high 
performance liquid chromatography coupled to hybrid quadrupole time of flight mass spectrometry 
(UHPLC-QTOF MS). Following this strategy, up to 10 phase I metabolites, together with some 
glucuronides and sulphates, were detected and tentative structures were proposed. Several compounds 
identified in this work have not been previously reported in the literature. 
 
Keywords: new psychoactive substances, 3,4-methylenedioxypyrovalerone, metabolism, urine, liquid 
chromatography, time-of-flight mass spectrometry.   
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1. INTRODUCTION 
The recreational drug market has changed notably in recent years to incorporate a range of new 
psychoactive substances (NPS), collectively known as “legal highs” or “designer drugs”. These are 
chemical analogues of illegally abused substances, usually devised to circumvent drug laws. Different 
reports have concluded that studies should be encouraged on the metabolism of NPS, as the unchanged 
forms may only be present in a low amount in human urine due to extensive metabolism [1-2]. That 
research would also help to select the most representative analytes for wastewater analysis in order to 
estimate the drug use, a recent approach known as sewage-based epidemiology [3]. 
Most metabolism studies are carried out under controlled conditions, and therefore both control/blank 
samples and samples collected after drug intake are available. This facilitates the comparison of their full-
spectrum acquisition MS data using commercial spectral/chromatographic comparative software. 
However, in some cases, such as the investigation reported in this paper, no control sample is available as 
the urine is collected from real consumers of NPS.  
In this work, urine from a 35 year-old man who self-reported to have taken 3,4-
methylenedioxypyrovalerone (MDPV) (see structure in Figure 1) was collected. MDPV is an analogue of 
pyrovalerone, a psycho stimulant that was used to treat lethargy and chronic fatigue in the 1970s, but was 
later withdrawn from the market because of problems with abuse and dependency [4-5]. In internet 
forums, MDPV is reported by users to be a potent psycho stimulant and psychedelic drug that is more 
active than methylphenidate when a mean dose of 10 mg is used intranasal, oral or rectal administration. 
Different episodes of cannibalism have been recently associated to the consumption of this drug [6-7].  
Ultra-high performance liquid chromatography coupled to high resolution mass spectrometry (UHPLC-
HRMS), specifically using a hybrid quadrupole-time of flight mass spectrometry (QTOF MS), has been 
used in this work for the investigation of human in vivo metabolites of this NPS in urine samples. The fact 
that no control sample was available complicated the study, and therefore an alternative strategy, based on 
common fragmentation pathway, was applied. This approach presumes a common fragmentation pathway 
for metabolites and the parent drug. Assuming that most metabolites share the same fragmentation 
pathway with the parent drug, specific narrow-window extracted ion chromatograms (nw-XICs) at the 
expected exact-mass m/z fragments were obtained from high-energy full-spectrum TOF MS acquisitions. 
The occurrence of chromatographic peaks at different retention times than the parent drug alerts the 
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investigator on the presence of potential drug metabolites. In this work, an extension of this approach has 
been applied, based not only on the fragmentation pathway of parent drug but also on that of the 
previously identified metabolites in the urine sample [8-9]. 
The use of MSE experiments (sequential acquisition of accurate mass data at low and high collision 
energy) was of great importance to ensure the success of this strategy, as it allows the fragmentation of 
compounds in the collision cell without any previous precursor ion selection. By applying low energy 
(LE), fragmentation is minimized and the information obtained normally corresponds to the parent 
molecule (commonly the (de)protonated molecule, but also adducts in some cases). However, at high 
energy (HE), fragmentation of the molecule is favoured, which is of much help in the elucidation process. 
So, both (de)protonated molecule and fragment ion data are available in a single acquisition without the 
need of selecting the precursor ion [10-11]. The resulting metabolites (both Phase I and Phase II) were 
detected and tentatively identified by accurate-mass full-spectrum measurements. 
Some MDPV metabolites, elucidated during in-vitro incubations with human liver microsomes [12-13] 
and administration studies in rats’ urine [12] have been afterwards detected in human urine [12]. This 
approach allows for the detection of a broad range of metabolites being either common metabolites 
between rats and humans or metabolites produced by human liver microsomes. In both methods, the 
resulting metabolites were analysed using gas chromatography/mass spectrometry as trimethylsilyl 
derivatives. The structure of the metabolites was further confirmed by accurate mass measurement using a 
LC-HR MS. In the last few years, some of the metabolites identified in the previous works [12-13] have 
been detected in human and rat plasma [14] or in urine of a patient who self-reported to have injected 
some doses of MDPV [15] by LC-HRMS(/MS). Paul et al [16] developed a LC-HRMS-QTOF method 
for the screening and semi-quantification of 62 compounds (including MDPV) in urine. Moreover, they 
identified a new hydrogenated metabolite of MDPV.  
However, some specific human metabolites not produced by liver microsomes might remain unnoticed. 
Thus studies devoted to the direct study of metabolites in human urine are needed. Finally, Mardal et al. 
[1] tentatively identified 12 microbial biotransformation products after incubation of MDPV in 
wastewater for 10 days. No additional MDPV biotransformation products could be found after incubating 
in rat urine and faeces samples. 
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2. MATERIALS AND METHODS 
2.1. Reagents and chemicals 
MDPV reference standard was acquired from Cayman Chemicals (Michigan, USA). HPLC-grade 
methanol (MeOH), acetonitrile (ACN), formic acid (HCOOH) (>98%) and sodium hydroxide (>99%) 
were purchased from ScharLab (Barcelona, Spain). . Leucine encephalin and β-glucuronidase type HP-2 
from Helix pomatia (≥100,000 units/mL, containing also ≤7,500 units/mL sulfatase) were purchased from 
Sigma Aldrich (St. Louis, MO, USA). HPLC-grade water was obtained from deionized water passed 
through a Milli-Q water purification system (Millipore, Bedford, MA, USA). 
 
2.2. Instrumentation 
An Acquity ultra-performance liquid chromatography (UPLC) system (Waters, Milford, MA, USA) was 
interfaced to a QTOF mass spectrometer (QTOF Xevo G2, Waters Micromass, Manchester, UK) using an 
orthogonal Z-spray electrospray interface. The LC separation was performed using Acquity UPLC BEH 
C18 1.7 µm particle size analytical column of 100 x 2.1 mm (from Waters), at a flow rate of 0.3 mL/min. 
The mobile phases used were A H2O and B MeOH, both with 0.01% (v/v) HCOOH. The proportion of 
MeOH was linearly increased as follows: 0 min, 10%; 14min, 90%; 16 min, 90%; 16.01 min, 10% and 18 
min, 10%. The injection volume was 20 µL. Nitrogen (Praxair, Valencia, Spain) was used as both the 
desolvation gas and the nebulising gas. The gas flow rate was set at 1000 L/h. The resolution of the TOF 
mass spectrometer was approximately 20,000 at full width half maximum at m/z 556. MS data were 
acquired over a m/z range of 50–1000 in a scan time of 0.4 s. The MCP detector potential was set to 3700 
V. Capillary voltages of 0.7 kV and -2.0 kV were used in positive and negative ionization modes, 
respectively. A cone voltage of 15 V was applied. The collision gas was argon (99.995%, Praxair). The 
interface temperature was set to 600 ºC and the source temperature to 130 ºC. The column temperature 
was set to 40ºC and the samples to 5ºC.  
For MSE experiments, two acquisition functions with different collision energies were created: the LE 
function with collision energy of 4 eV, and the HE function with a collision energy ramp ranging from 15 
to 30 eV.  
MS/MS experiments were also performed, using a cone voltage of 15 V and collision energies of 10, 15 
and 20 eV. For phase II metabolites, and in those cases in which a single abundant product ion was 
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obtained, a pseudo-MS3 experiment was performed by selecting as precursor ion the dominant in-source 
generated fragment at higher cone voltage (30 V) and acquiring the product ion scan of this in-source 
fragment.  
Calibration of the mass-axis from m/z 50 to 1000 was conducted daily with a 1:1 mixture of 0.05M 
NaOH/5% (v/v) HCOOH diluted (1:25) with water/ACN (20:80 v/v). 
For automated accurate mass measurement, the lock-spray probe was employed, pumping leucine 
enkephalin (10 mg/L) in ACN/water (50/50) at 0.1% HCOOH, at 20 µL/min through the lock-spray 
needle. The leucine enkephalin [M+H]+ ion (m/z 556.2771) for positive ionization mode, and [M-H]- ion 
(m/z 554.2615) for negative ionization, were used for recalibrating the mass axis and to ensure a robust 
accurate mass measurement over time. 
The data station operating software was MassLynx version 4.1 (Waters). 
 
2.3 Samples 
The patient was a 35-year old male, who was receiving treatment (valproic acid, paliperidone and 
amisulpride) since 2008 at Addictions Treatment Unit in Valencia (Spain). He has a history of cocaine-
related disorder and substance-induced psychoses. One year ago, the patient replaced cocaine for 
consumption of legal highs (MDPV) acquired in a smart shop. Recently, he developed a manic episode 
and  required hospitalization at a dual disorder unit in Castellón (Spain). After detoxification from legal 
highs, negative psychoses symptomatology persisted. The diagnosis was then changed from substance-
induced psychoses to schizoaffective disorder. For the metabolism study, urine sample from this patient 
with MDPV-related disorder was collected in a sterile bottle during hospitalization, which was stored at –
18 ºC until analysis. The study protocol was approved by the local ethical committee (Ref: DG NRI6 14-
24-10). The patient gave informed consent to the procedure. 
 
For the determination of phase I metabolites, 1 mL of centrifuged urine was buffered with 50 µL acetic 
acid/ammonium acetate (pH 5.5). After being hydrolyzed overnight with 2000 units of β-D-glucuronidase 
(also containing sulfatase) at 37 ºC [17], 50 µL of the hydrolyzed mixture were injected in the LC-QTOF 
MS system. 
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For direct determination of phase II metabolites, 1 mL of urine previously centrifuged (12,000 r.p.m., 10 
minutes), was two-fold diluted with Milli-Q water. After that, 50 µL were directly injected in the LC-
QTOF MS system.  
Additionally, the consumed legal high was also analyzed. For this purpose, 0.2 gr of the powder were 
extracted with acetone using ultrasounds. After that, the extract was 100-fold diluted with water and 
directly injected in the system.  
 
2.4 Data processing 
Acquisitions were performed in centroid, in both positive and negative ionisation mode. For all 
compounds detected, the accurate mass of protonated/deprotonated molecules was determined on the 
basis of averaged spectra obtained in the LE survey scan. Then, possible elemental compositions were 
calculated using the MassLynx elemental composition calculator with a maximum deviation of 2 mDa 
from the measured accurate mass. The maximum and minimum parameters were restricted considering 
the elemental composition and structure of MDPV (C16H21NO3) and the possibility of phase II 
metabolism, such as glucuronidation or sulphatation, as follows: C 0–25, H 0–40, N 0–4, O 0–10 and S 
0–1. The applied double-bond equivalent filter was set between –0.5 and 50. To calculate the elemental 
composition of product ions, parameters settings were restricted as a function of the calculated elemental 
composition of the (de)protonated molecule, while for neutral losses no restrictions were applied. 
Additionally, the option “even-electrons ions only” was selected for the precursor ion, and “odd- and 
even-electrons ions” for the product ions. 
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3. RESULTS AND DISCUSSION 
3.1. Mass spectrometric behaviour of MDPV 
Initially, an in-depth study of both the ionization and the fragmentation behavior of the parent drug is 
essential to obtain the origin and the structural information related with each valuable product ion. Due to 
the absence of acidic moieties, MDPV only showed ionization in positive mode with a prominent [M+H]+ 
at m/z 276.1590. Product ion scan experiments for MDPV produced a rich spectrum providing abundant 
structural information (Figure 1). 
Product ions could be classified based on the structural information provided. Thus, the ions at m/z 
126.1277 and m/z 84.0810 together with the neutral loss of 71.0721 Da (C4H9N; ion at m/z 205.0859) 
were indicative of the pyrrolidine function. The neutral loss of 43.0543 Da (C3H7; ion at m/z 233.1047) 
corresponded to the loss of the propyl chain. Additionally, the ions at m/z 149.0233, m/z 135.0440 and 
m/z 121.0293 indicated the presence of the methylenedioxy group coupled to the catechol moiety. Finally, 
the abundant ion at m/z 175.0753 was explained after the loss of both pyrrolydine and methylendioxy 
groups and, therefore this ion can be associated with the skeleton of the MDPV. 
 
3.2. Analytical strategy for detecting MDPV metabolites without control sample 
The detection of MDPV metabolites was performed assuming that MDPV and metabolites share a 
common fragmentation pathway. Thus, MDPV metabolites would share some fragments with the parent 
drug at the HE function. Therefore, MDPV metabolites can be detected by extracting the m/z of the 
MDPV product ions from the total ion current (TIC) chromatogram of the HE function. In our case, 8 nw-
XICs (0.02 Da mass window) corresponding to the m/z of the main MDPV product ions were extracted 
from the TIC of the HE function in the hydrolyzed urine sample.  
Every chromatographic peak with a retention time different than the parent drug was treated as a potential 
metabolite. The combined spectrum at the same retention time in the LE function allowed for establishing 
the accurate mass of the potential metabolite. Figure S.1 in Electronic supplementary Material shows 
the XICs for the 10 phase I metabolites detected. In this work, the mass accuracy obtained provided only 
one feasible formula for each metabolite considering the established mass error (2 mDa), except for 
metabolite M5, which provided two possibilities. The most coherent formula was found to be the one 
with lower mass deviation and was selected as molecular formula for the metabolite. 
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Table 1 shows a summary of the detection of MDPV metabolites by using common fragments extracted 
from the HE function. Some of the selected ions (e.g. m/z 149.0232, m/z 135.0440) allowed for the 
detection of only one metabolite (M5) whereas three different metabolites were detected by the selection 
of the ion at m/z 175.0752 (corresponding to the MDPV skeleton). Only the extraction of the ion at m/z 
233.1047 did not reveal any metabolite.  
Figure 2 shows the iterative workflow followed. No visible peaks were observed in the TIC of the 
hydrolised urine (Fig 2a). After applying the explained strategy performing the nw-XIC at m/z 175.0752 
in the HE function (Fig 2b) three chromatographic peaks were observed, corresponding to MDPV (at 5.5 
min) but also to two possible metabolites (M1 at 2.75 and M2 at 4.55 min). The HE spectra of both peaks 
were extracted (Fig 2c) as well as the LE spectra (Fig 2d), in order to known the accurate mass of both 
metabolites. When the nw-XIC was performed at m/z 278 in the LE function (Fig 2e, bottom), an 
additional chromatographic peak was observed at 5.37 min, surely related with a new metabolite isomeric 
to M2 but not sharing the fragment at m/z 175. In fact, this peak corresponds to M8. 
However, the use of common fragmentation pathway methodology presents some limitations when the 
metabolic reactions suffered by the parent drug shift the m/z values of the product ions of the metabolite. 
This fact can be even more important when these reactions alter the fragmentation pathway. An 
alternative to circumvent this drawback is to perform an iterative approach extracting also additional 
fragment ions from previously detected metabolites. Therefore, this approach assumes that a metabolite 
can share more structural characteristics with other metabolites than with its own parent drug. That was 
the case of M4 which exhibited a product ion at m/z 98.0602 absent in the product ion spectrum of the 
parent molecule. Thus, a new nw-XIC at this m/z was performed from the TIC acquired by high energy 
CID-TOF MS. This allowed the detection of M3, M6 and M7, that otherwise would have been lost (see 
Table 1).  
The application of the proposed strategy, based on acquisition in UHPLC-QTOF MS in MSE mode and 
posterior data processing based on common fragmentation pathway, to the hydrolyzed extract of the urine 
collected from a patient with MDPV-related disorder allowed for the detection of the parent drug and 10 
phase I metabolites.  
 
3.3. MDPV phase I metabolites 
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The accurate mass of each detected metabolite was studied in order to determine its molecular formula. 
The ionization of the metabolite in negative ionization mode was shown as indicative of the presence of 
acidic moieties (carboxylic or phenolic groups). Finally, QTOF MS/MS experiments were performed and 
the results compared with the behaviour of MDPV. Based on all this information, a putative structure for 
each metabolite was established. 
 
Metabolite M1 
M1 showed a [M+H]+at m/z 264.1593 which corresponds to C15H22NO3 (Table 2), i.e. a carbon atom less 
than MDPV. The product ion scan in positive mode (Table 3 and see Figure S.2 in Electronic 
Supplementary Material) was similar to the one obtained for MDPV. The presence of the ions at m/z 
126.1278, m/z 84.0809 and the neutral loss of 71.0732 Da (ion at m/z 193.0861) indicated an unaltered 
pyrrolidine ring. The neutral loss of 43.0546 Da (ion at m/z 221.1047) also indicated that the propyl chain 
was not modified in M1. On the other hand, the ions at m/z 123.0440 and m/z 137.0235 would correspond 
to the ions at m/z 135.0440 and m/z 149.0232 of MDPV, indicating that the loss of the carbon atom was 
produced in the catechol moiety. M1 also showed ionization in negative mode (Table 2) suggesting the 
presence of an acidic centre like a phenol. Based on these data, 1-(3,4-dihydroxyphenyl)-2-(1-
pyrrolidinyl)pentan-1-one was proposed as the structure for M1. 
 
Metabolite M2 
M2 showed a [M+H]+at m/z 278.1747 (C16H24NO3) which accounts for two hydrogen more than MDPV. 
Similarly to M1, M2 showed the ions at m/z 126.1277 and m/z 84.0809 and the neutral losses of 71.0732 
Da and 43.0544 Da (Table 3 and Figure S.3 in Electronic Supplementary Material), indicating that 
both the propyl and the pyrrolidine functions remained unaltered in M2. The ions at m/z 137.0597 and m/z 
151.0388 suggested a modification in the catechol moiety. The ionization in negative ionization mode of 
M2 (Table 2) was indicative of the presence of a phenolic function.  
The methylation of M1 via Catechol-O-Methyl Transferase (COMT) seems to be the metabolic pathway 
involved in the formation of M2. Since COMT shows preference for 3-methylation against 4-methylation 
[18], 1-(4-hydroxy-3-methoxyphenyl)-2-(1-pyrrolidinyl)pentan-1-one was proposed as the structure 
for M2. 
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Metabolite M3 
Although nominally M3 and M2 are isobaric (molecular mass 277), accurate mass measurements 
revealed that their molecular formula significantly differed (C16H23NO3 for M2 vs C15H19NO4 for M3). 
Based on its formula, M3 involved demethylation and oxidation. 
The product ion spectra (Table 3 and Figure S.4 in Electronic Supplementary Material) showed the 
ions at m/z 193.0861, 175.0752, 137.0236 and 123.0440 which are common to those observed for M1. 
Similar to M1, the occurrence of these ions suggested that demethylation took place in the catechol 
moiety. This hypothesis was supported by the fact that M3 also exhibited a [M-H]- in negative ionization 
mode (Table 2). On the other hand, the ions involving the pyrrolidin ring (m/z 126.1277, m/z 84.0810 and 
neutral loss of 71.0721 Da in the parent drug) contained all now an extra oxygen atom and were moved 
14 Da in M3 (m/z 140.1069, m/z 98.0601 and neutral loss of 85.0528 Da) indicating an oxidation in this 
moiety. Therefore, 1-(3,4-dihydroxyphenyl)-2-(1-pyrrolidonyl)pentan-1-one was proposed as the 
structure for M3.  
 
Metabolite M4 
M4 showed ionization in both positive and negative modes (Table 2) both corresponding to a molecular 
formula of C16H21NO5 i.e. M4 differs two oxygen atoms from MDPV.  
The product ion spectrum of M4 (Figure 3) showed a larger number of abundant ions than the one for 
MDPV (Figure 1). Among them, the ions at m/z 149.0232 and m/z 135.0443 indicated that the acetal 
moiety in the catechol remained unaltered in M4. Additionally, the ion at m/z 205.0873 suggested that all 
structural changes were focused on the pyrrolidin ring i.e. both oxygen atoms were added into this moiety. 
The ions at m/z 140.1071 and m/z 98.0602 were common to the ones observed in M3 in which an 
oxydation in the pyrrolidine ring was postulated. Product ion spectrum for M4 also showed ions 
indicating an extra molecule of water in this ring (m/z 158.1177 and the neutral loss of 103.0621 Da in 
contrast with the neutral loss of 85.0528 Da showed in M3). All this information taken together allowed 
for proposing 1-(3,4-methylenedioxyphenyl)-2-(1-succinamic acid)pentan-1-one as the structure for 
M4. The oxydative opening of the pyrrolidin ring seems to be the most feasible metabolic pathway for the 
generation of M4. 
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This opening is able to explain both the negative ionization observed despite the absence of any phenolic 
proton and the formation of all the product ions observed for M4 (Figure 3). The linear amine group 
together with the keto function at C1 facilitated the formation of the rearrangement previously reported for 
mephedrone [19]. 
 
Metabolite M5 
The molecular formula of M5 (C16H23NO5) implied the addition of two hydrogen and two oxygen atoms 
to MDPV. The product ion spectrum of M5 (Table 3 and Figure S.5 in Electronic Supplementary 
Material) was almost identical to the one for M4 but with most of the ions with a difference of 2 Da. On 
one hand, the ions at m/z 207.1035, m/z 151.0388 and m/z 137.0597 indicated the hydrolysis of the ketal 
moiety and the methylation of one of the hydroxyl groups of the catechol (as explained for M2). On the 
other hand, the ions at m/z 140.1069 and m/z 98.0606 are in agreement with an oxidation of the pyrrolidin 
ring (see M3) whereas the ion at m/z 158.1175 and the neutral loss of 103.0621 Da suggested the opening 
of the ring (as explained for M4). Based on these results, 1-(4-hydroxy-3-methoxyphenyl)-2-(1-
succinamic acid)pentan-1-one was proposed as structure for M5. 
 
Metabolite M6 and M7 
Both M6 and M7 had a molecular formula of C16H21NO4. Both metabolites were ionized in both positive 
and negative ionization modes (Table 2) suggesting the presence of an acidic centre in both structures. 
Their product ion spectra (Table 3 and Figures S.6 and S.7 in Electronic Supplementary Material) 
were almost identical. The ions at m/z 207.1026 and m/z 137.0598 would indicate hydrolysis of the ketal 
function and methylation of the phenolic group of the catechol (as explained for M2 and M5). This 
metabolic pathway would also explain the negative ionization observed for M6 and M7. Additionally, the 
ions at m/z 140.1073 and m/z 98.0603 suggested an oxidation in the pyrrolidine ring whereas the ion at 
m/z 175.0760 implied that both the keto function at C1 and the propyl chain remained unaltered.  
The product ion spectra of both M6 and M7 were identical suggesting that they were isomers. 
Methylation of both hydroxyl groups of the catechol seems to be the most feasible metabolic pathway for 
the generation of these isomers. Since COMT shows preference for 3-methylation [11], this pathway was 
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postulated to occur in the most abundant of both metabolites (M7) whereas 4-methylation was proposed 
for M6. 
Therefore, 1-(3-hydroxy-4-methoxyphenyl)-2-(1-pyrrolidonyl)pentan-1-one and 1-(4-hydroxy-3-
methoxyphenyl)-2-(1-pyrrolidonyl)pentan-1-one were proposed as the structures for M6 and M7 
respectively. 
 
Metabolite M8 
M8 was an isomeric metabolite of M2 (molecular formula C16H23NO3) i.e. it has two hydrogen atoms 
more than MDPV. However, the product ion spectrum of M8 (Table 3 and Figure S.8 in Electronic 
Supplementary Material) differed substantially from the one obtained for MDPV and M2. The spectrum 
was dominated by an abundant loss of water (ion at m/z 260.1641). This abundant loss was not observed 
in other metabolites as it is characteristic of aliphatic hydroxyl groups. For this reason, reduction of the 
keto function at C1 seemed to be the most feasible metabolic pathway involved in the generation of M8.  
Additionally, the ions at m/z 126.1278 and m/z 84.0809 and the neutral loss of 71.073 Da indicated an 
unaltered pyrrolidin ring whereas the neutral loss of 43. 0546 Da suggested that the propyl chain 
remained intact.  
Based on these data, 1-(3,4-methylenedioxyphenyl)-2-(1-pyrrolidinyl)pentan-1-ol was proposed as 
structure for M8.  
 
Metabolite M9 
Based on its molecular formula (C16H25NO4), M9 contains two hydrogen atoms and one oxygen more 
than MDPV. Similar to M2, the ions at m/z 151.0397 and m/z 137.0603 (Table 3 and Figure S.9 in 
Electronic Supplementary Material) indicated that M9 is a 3-methoxy-4-hydroxy-catechol-metabolite 
counting for the two extra hydrogen atoms. Therefore, hydroxylation of M2 seems to be the most feasible 
metabolic pathway involved in the formation of M9. 
The product ion spectrum was examined in order to elucidate the location of the hydroxyl group. Ions at 
m/z 151.0397 and m/z 137.0603 indicated that hydroxylation did not take place in the catechol moiety. 
The ion at m/z 72.0811 and the neutral loss of 71.073 Da (from m/z 294 to m/z 223 and from m/z 276 to 
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m/z 205) suggested that the pyrrolidine unit remained unaltered. However, nitrogen-containing ions at m/z 
98.0967 and m/z 142.1230 (not shown in other metabolites) indicated that hydroxylation took place close 
to the pyrrolidine ring.  
The neutral loss of the propyl chain (43 Da) was not observed in M9. In contrast, subsequent neutral 
losses of water and propylene (18 Da and 42 Da respectively) indicated that the propyl chain was 
hydroxylated. All this information taken together allowed for the proposal of 1-(4-hydroxy-3-
methoxyphenyl)-3-hydroxy-2-(1-pyrrolidinyl)pentan-1-one or 1-(4-hydroxy-3-methoxyphenyl)-4-
hydroxy-2-(1-pyrrolidinyl)pentan-1-one as a suitable structure for M9. With this information it is not 
possible to differentiate between both options. 
 
Metabolite M10 
M10 was an isomer of M9 (C16H25NO4) and also showed the ions at m/z 137.0602 and m/z 151.0395 
indicative of 3-methoxy-4-hydroxy-catechol metabolites. Therefore, in the same way as M9, 
hydroxylation of M2 was also considered as metabolic pathway for obtaining M10. 
Product ion spectrum of M10 did exhibit neither the ions at m/z 72 and m/z 84 nor the neutral loss of 71 
Da corresponding to the pyrrolidin function. In contrast, it showed a neutral loss of 87.0684 Da (ion at 
m/z 207.1023) and the ions at m/z 100.0759 and 88.0761 (Table 3 and Figure S.10 in Electronic 
Supplementary Material). These results suggested that the hydroxyl group was placed on the 
pyrrolidine ring. Thus, 1-(4-hydroxy-3-methoxyphenyl)-2-(2-hydroxypyrrolidinyl)pentan-1-one or 1-
(4-hydroxy-3-methoxyphenyl)-2-(3-hydroxypyrrolidinyl)pentan-1-one could be proposed as the 
structure for M10. We have selected the first option as most plausible as it would be related with M6/M7, 
although the second candidate could not be discarded.  
 
3.4. MDPV phase II metabolites 
Once the 10 phase I metabolites were tentatively elucidated, nw-XICs at the calculated m/z for the 
corresponding phase II metabolites (concretely glucuronides and sulphates) were reconstructed from the 
LE data in the non-hydrolyzed urine. In these cases, MS2 but also MS3 experiments were performed. In 
the latter case, the main product ion generated in the MS2 spectrum (corresponding to the loss of the 
sulphate or glucuronide group) was selected as precursor ion by increasing the cone voltage and acquiring 
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the product ion scan of the generated in-source fragment. The structure of the non-conjugated part could 
be confirmed by comparing the corresponding MS3 fragmentation with the MS/MS spectra of the phase I 
metabolites. Using this approach, up to 7 glucuronides and 5 sulfates were detected (Table 2). 
 
3.5. Metabolic pathway for MDPV 
All this information taken together allowed for the proposal of a metabolic pathway for MDPV (Figure 
4). The main reactions involved in MDPV metabolism are (i) hydrolysis of the ketal moiety of the 
catechol, (ii) methylation at C3’, (iii) oxidation of the pyrrolidine ring, (iv) oxidative opening of the 
pyrrolidine ring, (v) reduction of the carbonyl group and (vi) hydroxylation.  
In comparison to previously reported data, of the 10 tentatively identified metabolites, 5 have also been 
detected in rat urine samples (M1, M2, M3, M4, M7) [12,14,16], 6 in human urine (M1, M2, M3, M7, 
M8, M9) [12,15,16] and 3 after microbial biotransformation (M1, M2, M10) [1].  
It is remarkable that, up to our knowledge, 2 of the metabolites identified in this paper have not been 
reported in the literature, concretely M5 and M6. In the case of M5, the same metabolic pathway has been 
proposed for similar compounds like α-Pyrrolidinovalerophenone [20]. Regarding M6, this metabolite 
can be explained after the combination of two well-documented metabolic pathways for these compounds, 
i.e. oxidation of the pyrrolidin ring, hydrolysis of the ketal moiety of the catechol and methylation at C3’. 
Reference standards are not commercially available for these metabolites, and therefore their identity, 
although strongly supported by our QTOF MS accurate-mass data, could not be unequivocally confirmed. 
In summary, the proposed strategy allowed for the detection of MDPV and 10 potential metabolites. The 
use of a large volume injection (50 µL in a 1.7 µm LC column) improved the sensitivity of the method 
and the minimum sample preparation step minimised the possibility of losing part of the metabolites 
during the extraction process. However, both aspects of the experimental design might contribute to an 
inappropriate chromatographic behaviour. Therefore, the presence of additional isomers which might be 
not properly resolved under the experimental conditions cannot be discarded. 
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CONCLUSIONS  
The potential of UHPLC-QTOF MSE for the investigation of NPS metabolites in consumers’ urine 
samples is illustrated, taking MDPV as a case of interest. In this paper, only a grab urine sample from a 
patient with MDPV-related disorder was available. Even in this case, where a control sample was not 
available, it was feasible to investigate the presence of known and unknown metabolites. Using a strategy 
based on the common fragmentation pathway of parent drug and metabolites, the detection of seven phase 
I metabolites was possible. The urinary excretion of some of them as glucuronides and sulfates was also 
identified. This strategy was extended to a second level, considering a common fragmentation pathway 
between a known metabolite, already detected in the sample, and other potential metabolites. This made 
the discovery of three additional metabolites possible. This strategy was based on the use of a QTOF 
instrument, which allows the full-spectrum acquisition in TOF MS mode with and without promoting 
fragmentation in the collision cell (MSE acquisition). It was essential to first study the fragmentation 
pathway of the parent drug, which was facilitated by the accurate mass information provided by this 
analyzer. In addition, some MS/MS experiments were also performed, which gave relevant information 
about product ions and allowed elimination of interferences co-eluting with the analytes. The use of MSE 
together with additional analysis by MS/MS provided an excellent way of elucidating and/or confirming 
the presence of discovered metabolites. Data reported in this paper will be of help to develop future target 
quantitative methods for MDPV in urine focused on the most relevant metabolites present in the samples. 
Furthermore, these data may also be used with other purposes, e.g. to facilitate wastewater analysis in 
sewage-based epidemiology studies in order to estimate illicit drug consumption of a population. 
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FIGURE LEGENDS 
Fig. 1. Product ion spectrum of MDPV (20 eV) and proposed fragmentation pathway.  
Fig. 2. (a1)Total Ion Current (TIC) chromatogram of the low energy function (LE) of the hydrolysed 
urine (a2) TIC of the high energy function (HE) of the hydrolysed urine (only showed from 1 to 7 min); 
(b) nw-XIC at m/z 175.075 in HE function; (c) HE spectra for peaks at 2.75 and 4.55 min; (d) LE spectra 
for peaks at 2.75 and 4.55 min; (e) nw-XIC for peaks detected at 2.75 and 4.55 min in LE function 
Fig. 3. Product ion spectrum of M4 (20 eV) and proposed fragmentation pathway. 
Fig.4.Metabolic pathway proposed for MDPV. U: metabolites excreted unconjugated, G: metabolites 
excreted as glucuronides, S: metabolites excreted as sulfates. * M6 (not shown in the Figure) is the C4’ 
methylated isomer of M7 which is methylated in C3’ (shown in the Figure) 
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TABLES 
Table 1. Detection of MDPV metabolites by common fragments, extracted in the high collision energy 
function of the MSEacquisition mode. 
 
  Structural features  
  
 
 
Base 
compound 
Fragment 
(m/z) 
Propyl  
chain 
Pyrrolidin 
 ring 
Catechol 
 substitution 
Detected metabolites 
MDPV 233.1047 - Unchanged Unchanged - 
      
 205.0859 Unchanged  Unchanged M4, M9 
      
 175.0752 Unchanged   M1, M2 (M8) 
      
 149.0232  - Unchanged M5 
      
 135.0440   Unchanged M5 
      
 126.1277 Unchanged Unchanged  M1, M2 
M2 137.0597   3’-methoxy 
4’-hydroxy 
M10 
M4 98.0602  Oxydized  M3, M5, M6, M7 
*Although all fragment ions for all metabolites were used for the iterative process, only those which 
contribute to find additional metabolites have been included in this table. 
 
 
 
 
O
NO
O
Catechol
Pyrrolidin
Propyl
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Table 2. Retention time, ionization behaviour and phase I/phase II species found for the detected metabolites. 1 
Compound Rt (min) 
Ionization phase I/phase II metabolism 
Ionization 
Mode Species 
Elemental 
composition 
m/z Error (mDa)  Unconjugated Glucuronide Sulphate 
MDPV 5.47 ESI+ [M+H]+ C16H22NO3 276.1590 -1.0   n.d. n.d. 
M1 2.75 ESI+ [M+H]+ C15H22NO3 264.1593 -0.7  n.d.   
 
 ESI- [M-H]- C15H20NO3 262.1445 0.2     
M2 4.57 ESI+ [M+H]+ C16H24NO3 278.1747 -0.9     
 
 ESI- [M-H]- C16H22NO3 276.1589 -1.5     
M3 7.85 ESI+ [M+H]+ C15H20NO4 278.1389 -0.3  n.d. n.d.  
 
 ESI- [M-H]- C15H18NO4 276.1227 -0.2     
M4 5.7 ESI+ [M+H]+ C16H22NO5 308.1494 -0.4   n.d. n.d. 
 
 ESI- [M+H]- C16H20NO5 306.1331 -1.0     
M5 4.5 ESI+ [M+H]+ C16H24NO5 310.1646 -0.8   n.d.  
 
 ESI- [M-H]- C16H22NO5 308.1488 -1.0     
M6 8.52 ESI+ [M+H]+ C16H22NO4 292.1554 0.5  n.d.  n.d. 
 
 ESI- [M-H]- C16H20NO4 290.1392 0     
M7 8.78 ESI+ [M+H]+ C16H22NO4 292.1551 0.2  n.d. . n.d. 
 
 ESI- [M-H]- C16H20NO4 290.1390 -0.2     
M8 5.3 ESI+ [M+H]+ C16H24NO3 278.1747 -0.9   n.d. n.d. 
M9 2.8 ESI+ [M+H]+ C16H24NO4 294.1709 0.4  n.d. n.d.  
M10 4.4 ESI+ [M+H]+ C16H24NO4 294.1707 0.2  n.d.  n.d. 
 2 
 3 
23 
 
Table 3. Product ions found in positive ionization mode for the detected metabolites. 4 
Metabolite m/z Error 
(mDa) 
Elemental 
composition 
Precursor ion Product ion  Abundance 
(%) 
Error 
(mDa) 
Formula 
MDPV 276.1590 -1.0 C16H22NO3 276 233.1047 8 -0.5 C13H15NO3 
 
    205.0859 86 -0.6 C12H13O3 
 
    175.0753 92 -0.6 C11H11O2 
 
    149.0233 40 -0.7 C8H5O3 
 
    135.0440 70 -0.6 C8H7O2 
 
    126.1277 90 -0.6 C8H16N 
 
    121.0293 2 0.3 C7H5O2 
 
    84.0810 4 -0.3 C5H10N 
M1 264.1593 -0.7 C15H22NO3 264 221.1047 8 -0.5 C12H15NO3 
 
    193.0861 47 -0.4 C11H13O3 
 
    175.0754 35 -0.5 C11H11O2 
 
    165.0912 5 -0.4 C10H13O2 
 
    137.0235 32 -0.4 C7H5O3 
 
    126.1278 72 -0.5 C8H16N 
 
    123.0440 70 -0.6 C7H7O2 
 
    84.0809 5 -0.4 C5H10N 
 
    72.0809 44 -0.4 C4H10N 
M2 278.1747 -0.9 C16H24NO3 278 235.1203 4 -0.5 C13H17NO3 
 
    207.1015 39 -0.6 C12H15O3 
 
    175.0751 100 -0.8 C11H11O2 
 
    151.0388 30 -0.7 C8H7O3 
 
    137.0597 33 -0.6 C8H9O2 
 
    126.1277 75 -0.6 C8H16N 
 
    84.0809 4 -0.4 C5H10N 
 
    72.0808 12 -0.5 C4H10N 
M3 278.1389 -0.3 C15H20NO4 278 260.1282 8 -0.5 C15H18NO3 
 
    193.0861 8 -0.4 C11H13O3 
 
    175.0752 10 -0.7 C11H11O2 
 
    140.1069 100 -0.6 C8H14NO 
 
    137.0236 2 -0.3 C7H5O3 
 
    123.0440 11 -0.6 C7H7O2 
 
    98.0601 25 -0.5 C5H8NO 
 
    86.0602 11 -0.4 C4H8NO 
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Metabolite m/z Error 
(mDa) 
Elemental 
composition 
Precursor ion Product ion  Abundance 
(%) 
Error 
(mDa) 
Formula 
M4 308.1494 -0.4 C16H22NO5 308 290.1387 100 -0.5 C16H20NO4 
 
    272.1283 40 -0.4 C16H18NO3 
 
    260.1283 50 -0.4 C15H18NO3 
 
    242.1179 20 -0.2 C15H16NO2 
 
    230.0814 27 -0.3 C13H12NO3 
 
    214.1230 27 -0.2 C14H16NO 
 
    205.0873 53 0.8 C12H13O3 
 
    204.1017 54 -0.8 C12H14NO2 
 
    203.0943 21 -0.3 C12H13NO2 
 
    175.0756 48 -0.3 C11H11O2 
 
    174.0916 40 -0.3 C11H12NO 
 
    158.1177 18 -0.4 C8H16NO2 
 
    149.0232 12 -0.7 C8H5O3 
 
    140.1071 100 -0.4 C8H14NO 
 
    135.0443 30 -0.3 C8H7O2 
 
    98.0602 14 -0.4 C5H8NO 
 
    87.0443 27 -0.3 C4H7O2 
M5 310.1646 -0.8 C16H24NO5 310 292.1540 90 -0.9 C16H22NO4 
 
    274.1435 40 -0.8 C16H20NO3 
 
    260.1279 60 -0.8 C15H18NO3 
 
    242.1184 22 0.3 C15H16NO2 
 
    232.0977 20 0.3 C13H14NO3 
 
    207.1035 28 -1.3 C12H15O3 
 
    206.1171 48 -1.0 C12H16NO2 
 
    205.1098 20 -0.5 C12H15NO2 
 
    175.0757 62 -0.2 C11H11O2 
 
    174.0912 55 -0.7 C11H12NO 
 
    158.1175 30 -0.6 C8H16NO2 
 
    151.0388 13 -0.7 C8H7O3 
 
    140.1069 100 -0.6 C8H14NO 
 
    137.0597 14 -0.6 C8H9O2 
 
    104.0711 10 -0.1 C4H10NO2 
 
    98.0606 13 0 C5H8NO 
 
    87.0442 25 -0.4 C4H7O2 
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Metabolite m/z Error 
(mDa) 
Elemental 
composition 
Precursor ion Product ion  Abundance 
(%) 
Error 
(mDa) 
Formula 
M6 292.1554 0.5 C16H22NO4 292 274.1440 5 -0.3 C16H20NO3 
 
    207.1026 8 0.5 C12H15O3 
 
    175.0760 10 0.1 C11H11O2 
 
    140.1073 100 -0.2 C8H14NO 
 
    137.0598 10 -0.5 C8H9O2 
 
    98.0603 20 -0.3 C5H8NO 
 
    86.0600 3 -0.6 C4H8NO 
M7 292.1546 0.2 C16H22NO4 292 274.1439 5 -0.4 C16H20NO3 
 
    207.1021 5 0 C12H15O3 
 
    175.0759 8 0 C11H11O2 
 
    140.1072 100 -0.3 C8H14NO 
 
    137.0601 6 -0.2 C8H9O2 
 
    98.0604 20 -0.2 C5H8NO 
 
    86.0603 3 -0.3 C4H8NO 
M8 278.1747 -0.9 C16H24NO3 278 260.1641 100 -1.0 C16H22NO2 
 
    217.1095 58 -0.8 C13H15NO2 
 
    207.1017 3 -0.4 C12H15O3 
 
    175.0754 8 -0.5 C11H11O2 
 
    159.0804 6 -0.6 C11H11O 
 
    126.1278 6 -0.5 C8H16N 
 
    84.0809 2 -0.4 C5H10N 
 
    72.0808 3 -0.5 C4H10N 
M9 294.1709 0.4 C16H24NO4 294 276.1595 8 -0.5 C16H22NO3 
 
    234.1135 58 0.5 C13H16NO3 
 
    223.0973 4 0.3 C12H15O4 
 
    216.1026 4 0.2 C13H14NO2 
 
    205.0867 10 0.2 C12H13O3 
 
    200.1074 19 -0.1 C13H14NO 
 
    173.0614 2 1.1 C11H9O2 
 
    177.0545 5 -0.7 C10H9O3 
 
    151.0397 9 0.2 C8H7O3 
 
    142.1230 27 -0.2 C8H16NO 
 
    137.0603 20 0 C8H9O2 
 
    98.0967 9 -0.3 C6H12N 
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Metabolite m/z Error 
(mDa) 
Elemental 
composition 
Precursor ion Product ion  Abundance 
(%) 
Error 
(mDa) 
Formula 
 
    72.0811 10 -0.2 C4H10N 
M10 294.1707 0.2 C16H24NO4 294 276.1600 4 0 C16H22NO3 
 
    251.1154 3 -0.4 C13H17NO4 
 
    248.1650 12 -0.1 C15H22NO2 
 
    207.1023 30 0.2 C12H15O3 
 
    175.0759 78 0 C11H11O2 
 
    151.0395 36 0 C8H7O3 
 
    142.1229 65 -0.3 C8H16NO 
 
    137.0602 24 -0.1 C8H9O2 
 
    100.0759 4 -0.3 C5H10NO 
 
    88.0761 21 -0.1 C4H10NO 
 
    70.0654 4 -0.3 C4H8N 
 5 
 6 
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